AbbVie (ABBV)
253.30
0.00 (0.00%)
Upcoming Events
Latest Headlines
Abbvie (ABBV) PT Raised to $282 at Canaccord
July 22, 2026 6:39 AM - StreetInsider
EU approves AbbVie's Boey for short-duration frown line treatment
July 17, 2026 8:03 AM - StreetInsider
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in ad
July 17, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $260 at Citi
July 15, 2026 5:02 AM - StreetInsider
SkinMedica launches advisory board and expands R&D lab in Irvine
July 14, 2026 8:05 AM - StreetInsider
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
July 14, 2026 8:05 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $300 at BMO Capital
July 13, 2026 7:31 AM - StreetInsider
Abbvie (ABBV) PT Raised to $280 at RBC Capital
July 10, 2026 7:30 AM - StreetInsider
Abbvie (ABBV) PT Raised to $295 at Wells Fargo
July 10, 2026 6:35 AM - StreetInsider
Abbvie (ABBV) PT Raised to $280 at JPMorgan
July 9, 2026 7:59 AM - StreetInsider
Abbvie (ABBV) PT Raised to $261 at Guggenheim
July 9, 2026 7:09 AM - StreetInsider
AbbVie updates 2026 EPS guidance after $291M IPR&D charge
July 6, 2026 4:14 PM - StreetInsider
Form 8-K AbbVie Inc. For: Jul 06
July 6, 2026 4:12 PM - SEC Filing
EU approves AbbVie's Tepkinly combo for follicular lymphoma
July 6, 2026 1:45 PM - StreetInsider
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
July 6, 2026 1:45 PM - PR NewsWire
Abbvie (ABBV) PT Raised to $265 at Cantor Fitzgerald: Broadly Strong Q2 Results Expected
July 6, 2026 6:43 AM - StreetInsider
Abbvie (ABBV) PT Raised to $300 at HSBC
July 6, 2026 1:34 AM - StreetInsider
Form 4 AbbVie Inc. For: Jul 01 Filed by: RAPP EDWARD J
July 2, 2026 5:01 PM - SEC Filing
Form 4 AbbVie Inc. For: Jun 30 Filed by: Quaggin Susan E
July 2, 2026 5:00 PM - SEC Filing
A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
July 1, 2026 9:05 AM - StreetInsider
RBC Capital Reiterates Outperform Rating on Abbvie (ABBV)
July 1, 2026 8:01 AM - StreetInsider
U.S. House committee opens investigation into Merck, AbbVie China drug trials - Reuters
June 30, 2026 6:02 AM - StreetInsider
FDA selects 7 companies for domestic drug manufacturing pilot
June 29, 2026 4:20 PM - StreetInsider
AbbVie's epcoritamab combo meets primary endpoint in lymphoma trial
June 29, 2026 4:15 PM - StreetInsider
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
June 29, 2026 4:15 PM - PR NewsWire
AbbVie's Rinvoq gets positive EU panel opinion for hair loss
June 29, 2026 3:10 AM - StreetInsider
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
June 29, 2026 3:10 AM - PR NewsWire
EU panel backs AbbVie's Rinvoq for vitiligo treatment
June 29, 2026 3:00 AM - StreetInsider
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
June 29, 2026 3:00 AM - PR NewsWire
FDA approves AbbVie's Skyrizi for children with psoriatic disease
June 26, 2026 4:52 PM - StreetInsider
SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease
June 26, 2026 4:51 PM - PR NewsWire
AbbVie to Host Second-Quarter 2026 Earnings Conference Call
June 26, 2026 8:00 AM - PR NewsWire
The Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for It
June 25, 2026 9:04 AM - StreetInsider
Form 11-K AbbVie Inc. For: Dec 31
June 24, 2026 5:27 PM - SEC Filing
BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026
June 24, 2026 8:00 AM - PR NewsWire
Bernstein SocGen's Thoughts on Abbvie (ABBV) Following APGE Acquisition
June 23, 2026 9:12 AM - StreetInsider
Health Canada approves AbbVie's Boey for frown line treatment
June 23, 2026 8:00 AM - StreetInsider
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patie
June 23, 2026 8:00 AM - PR NewsWire
Abbvie (ABBV) Reiterated at Overweight by Cantor Fitzgerald after Analyst Call
June 23, 2026 7:22 AM - StreetInsider
Abbvie (ABBV) PT Raised to $273 at Canaccord
June 23, 2026 7:06 AM - StreetInsider
EU approves AbbVie's Maviret for acute hepatitis C treatment
June 23, 2026 5:39 AM - StreetInsider
AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
June 23, 2026 5:00 AM - PR NewsWire
EU approves AbbVie's Skyrizi for children with plaque psoriasis
June 23, 2026 4:09 AM - StreetInsider
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
June 23, 2026 3:00 AM - PR NewsWire
Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal
June 22, 2026 10:16 AM - StreetInsider
Form 8-K AbbVie Inc. For: Jun 18
June 22, 2026 7:11 AM - SEC Filing
AbbVie sharpens immunology focus with $10.9 billion Apogee deal
June 22, 2026 7:09 AM - StreetInsider
AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion
June 22, 2026 7:01 AM - StreetInsider
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
June 22, 2026 7:00 AM - PR NewsWire
AbbVie (ABBV) call put ratio 2.2 calls to 1 put into near deal to acquire Apogee Therapeutics (APGE), FT reports
June 22, 2026 6:23 AM - StreetInsider
AbbVie (ABBV) Declares $1.73 Quarterly Dividend; 3.2% Yield
June 18, 2026 4:07 PM - StreetInsider
AbbVie Declares Quarterly Dividend
June 18, 2026 4:06 PM - PR NewsWire
Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower
June 16, 2026 8:15 AM - PR NewsWire
FDA approves ABBVIE neck wrinkle injectable SKINVIVE by JUVÉDERM
June 16, 2026 8:01 AM - StreetInsider
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
June 16, 2026 8:00 AM - PR NewsWire
Leerink highlights drug demand rebound after Memorial Day
June 12, 2026 2:42 PM - StreetInsider
AbbVie presents nine-year venetoclax trial results at EHA congress
June 12, 2026 3:03 AM - StreetInsider
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resu
June 12, 2026 3:00 AM - PR NewsWire
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics
June 10, 2026 8:00 AM - PR NewsWire
AbbVie to present blood cancer data at EHA 2026
June 8, 2026 8:01 AM - StreetInsider
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
June 8, 2026 8:00 AM - PR NewsWire
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 2, 2026 8:00 AM - PR NewsWire
Form SD AbbVie Inc.
June 1, 2026 5:17 PM - SEC Filing
AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations
May 29, 2026 8:00 AM - StreetInsider
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
May 29, 2026 8:00 AM - PR NewsWire
FDA approves AbbVie's DECNUPAZ for rare blood cancer treatment
May 27, 2026 6:18 PM - StreetInsider
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatme
May 27, 2026 6:18 PM - PR NewsWire
FDA approves AbbVie's pivekimab sunirine-PVZY for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy
May 27, 2026 3:38 PM - StreetInsider
Form 144 AbbVie Inc. Filed by: Alpern Robert J
May 26, 2026 4:19 PM - SEC Filing
AbbVie receives positive EU committee opinion for hepatitis C drug
May 22, 2026 8:00 AM - StreetInsider
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
May 22, 2026 8:00 AM - PR NewsWire
AbbVie to present oncology pipeline data at 2026 ASCO meeting
May 22, 2026 5:31 AM - StreetInsider
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
May 21, 2026 6:46 PM - PR NewsWire
Allergan Aesthetics receives positive opinion for Boey botulinum toxin
May 21, 2026 4:10 PM - StreetInsider
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
May 21, 2026 4:10 PM - PR NewsWire
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Abbvie (ABBV) PT Lowered to $235 at Evercore ISI
May 15, 2026 7:15 AM - StreetInsider
Abbvie (ABBV) PT Raised to $298 at Piper Sandler
May 14, 2026 7:30 AM - StreetInsider
Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
May 13, 2026 8:33 AM - StreetInsider
CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
May 13, 2026 8:30 AM - Globe NewsWire
Form 8-K AbbVie Inc. For: May 08
May 12, 2026 5:02 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: FALK THOMAS J
May 12, 2026 5:01 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Quaggin Susan E
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: MEYER MELODY B
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: FREYMAN THOMAS C
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: RAPP EDWARD J
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Roberts Rebecca B
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Davis Jennifer L.
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: Hart Brett J
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: WADDELL FREDERICK H
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: BURNSIDE WILLIAM H.L.
May 12, 2026 5:00 PM - SEC Filing
Form 4 AbbVie Inc. For: May 08 Filed by: AUSTIN ROXANNE S
May 12, 2026 5:00 PM - SEC Filing
Form 10-Q AbbVie Inc. For: Mar 31
May 8, 2026 12:30 PM - SEC Filing
Health officials explore restrictions on certain SSRI antidepressants - Reuters
May 8, 2026 12:04 PM - StreetInsider
AbbVie to Present at the Bank of America Securities Healthcare Conference
May 6, 2026 8:00 AM - PR NewsWire
AbbVie presents inflammatory bowel disease data at medical conference
May 5, 2026 8:05 AM - StreetInsider
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
May 5, 2026 8:05 AM - PR NewsWire
NImmune Biopharma Announces Presentations at Digestive Disease Week 2026 Supporting a Differentiated Profile and Superior Efficacy of Oral, Once-Daily NIM-1324 for IBD
May 5, 2026 8:00 AM - BizWire
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
April 30, 2026 3:00 PM - Globe NewsWire
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
April 30, 2026 9:01 AM - PR NewsWire
Abbvie (ABBV) PT Raised to $278 at Morgan Stanley
April 30, 2026 7:57 AM - StreetInsider
Abbvie (ABBV) PT Raised to $265 at Canaccord
April 30, 2026 6:35 AM - StreetInsider
BofA Securities Upgrades Abbvie (ABBV) to Buy
April 30, 2026 6:06 AM - StreetInsider
Abbvie (ABBV) PT Raised to $244 at Goldman Sachs
April 30, 2026 4:25 AM - StreetInsider
Form SCHEDULE 13G AbbVie Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 4:39 PM - SEC Filing
AbbVie shares gain on earnings beat, raised guidance
April 29, 2026 8:09 AM - StreetInsider
Form 8-K AbbVie Inc. For: Apr 29
April 29, 2026 7:50 AM - SEC Filing
AbbVie (ABBV) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
April 29, 2026 7:48 AM - StreetInsider
AbbVie Reports First-Quarter 2026 Financial Results
April 29, 2026 7:47 AM - PR NewsWire
AbbVie Q1 earnings preview: analysts eye immunology growth trends
April 29, 2026 12:00 AM - StreetInsider
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
April 28, 2026 8:00 AM - PR NewsWire
EvolveImmune receives $18 million milestone payment from ABBV partnership
April 28, 2026 7:01 AM - StreetInsider
EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
April 28, 2026 7:00 AM - Globe NewsWire
AbbVie submits FDA application for SKYRIZI subcutaneous dosing
April 27, 2026 8:05 AM - StreetInsider
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
April 27, 2026 8:05 AM - PR NewsWire
Full Article List
